Compare Boston Scientific Corporation (BSX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Boston Scientific Corporation trades at $51.54 (market cap $74.19B), while YieldMax NVDA Option Income Strategy ETF trades at $13.06. Which is the better fit depends on your goals.
| BSX | NVDY | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $17.96 |
52-Week Low | $42.63 | $11.58 |
Enterprise Value | $86.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
NVDY trades at $13.055, up 2.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.15 per share. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions, attracting income-focused investors.
The outlook for NVDY hinges on NVIDIA's volatility, which drives option premiums and dividends. However, investors sacrifice significant upside potential in NVIDIA's stock gains. Risks include underperformance versus direct NVIDIA ownership and fee drag. The ETF suits income seekers but may disappoint those seeking capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
